Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Turn Therapeutics Inc. incurred term loan of up to $25.0 million with Avenue Venture Opportunities Fund II, L.P. at greater of (x) the sum of 5.50% plus the prime rate as reported in The Wall Stre maturing October 1, 2029.
- Instrument
- term loan
- Principal
- up to $25.0 million
- Counterparty
- Avenue Venture Opportunities Fund II, L.P.
- Rate
- greater of (x) the sum of 5.50% plus the prime rate as reported in The Wall Stre
- Maturity
- October 1, 2029
- Event
- incurrence
Exact text from the filing
On March 23, 2026 (the “Closing Date”), Turn Therapeutics Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan and Security Agreement”) and a Supplement to the Loan and Security Agreement (the “Supplement” and, together with the Loan and Security Agreement, the “Loan Agreement”), with Avenue Venture Opportunities Fund II, L.P., as administrative agent, collateral agent (in such capacities, the “Agent”) and as a lender (in such capacity, together with each other lender from time to time party thereto, the “Lender”). The Loan Agreement makes available to the Company term loans in an aggregate principal amount of up to $25.0 million with (i) $7.0 million funded within one business day of the Closing Date (“Tranche 1”) and (ii) up to $8.0 million to be made available to the Company between September 1, 2026 and March 31, 2027, subject to, among other things, the Company’s achievement of specified clinical and financing milestones (“Tranche 2”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Turn Therapeutics Inc. issued shares of Common Stock with an aggregate value of $1.2 million of common stock to Avenue Venture Opportunities Fund II, L.P..
- Security
- common stock
- Shares
- shares of Common Stock with an aggregate value of $1.2 million
- Purchaser
- Avenue Venture Opportunities Fund II, L.P.
Exact text from the filing
the Company issued to the Lender shares of Common Stock with an aggregate value of $1.2 million, with the exact number of shares calculated by dividing (i) $1.2 million by (ii) the volume-weighted average price of the Common Stock, determined for the five (5) consecutive trading days ending on the last trading day immediately preceding the Closing Date (the “Equity Grant”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Turn Therapeutics Inc. entered into Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P. valued at up to $25.0 million (effective 2026-03-23).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Avenue Venture Opportunities Fund II, L.P.
- Value
- up to $25.0 million
- Effective
- 2026-03-23
Exact text from the filing
On March 23, 2026 (the “Closing Date”), Turn Therapeutics Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan and Security Agreement”) and a Supplement to the Loan and Security Agreement (the “Supplement” and, together with the Loan and Security Agreement, the “Loan Agreement”), with Avenue Venture Opportunities Fund II, L.P., as administrative agent, collateral agent (in such capacities, the “Agent”) and as a lender
View on SEC.gov